Clinical commissioning policy: Rituximab

This clinical commissioning policy sets out the criteria for Rituximab as a treatment option through routine commissioning for nodal/paranodal antibody positive inflammatory/autoimmune neuropathy in adults and postpubescent children.
Source: NHS Networks - Category: UK Health Source Type: news